SCHEMBL13547356

SCHEMBL13547356

O=C(NC1CCCN(C(=O)O)CCC1)ON1C(=O)CCC1=O

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ KDM4E B2RXH2 3/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ EPHX1 P07099 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ MGLL Q99685 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NPC1 O15118 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ TSHR P16473 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3612641 0.97 HTT (0.36) HTTALDH1A1RAB9AKDM4ECA1
SCHEMBL3617697 0.97 HTT (0.36) HTTALDH1A1RAB9AKDM4ECA1
SCHEMBL12811829 0.86 EPHX1 (0.42) ALDH1A1RAB9AKDM4ESMN1; SMN2EPHX1
SCHEMBL2676319 0.85 EPHX1 (0.49) HTTALDH1A1RAB9AKDM4ESMN1; SMN2
SCHEMBL13547213 0.85 EPHX1 (0.49) HTTALDH1A1RAB9AKDM4ESMN1; SMN2
SCHEMBL13547225 0.82 KDM4E (0.46) HTTALDH1A1RAB9AKDM4ESMN1; SMN2
SCHEMBL13547377 0.82 KDM4E (0.43) ALDH1A1KDM4EMAPT
SCHEMBL13809020 0.80 ALDH1A1 (0.34) ALDH1A1RAB9ASMN1; SMN2EPHX1POLB
SCHEMBL13547226 0.80 RAB9A (0.34) ALDH1A1RAB9AKDM4ESMN1; SMN2EPHX1
SCHEMBL3616970 0.79 SMN1; SMN2 (0.51) HTTALDH1A1RAB9ASMN1; SMN2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009957-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MERCK SHARP & DOHME CORP. 2010-01-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009957-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MGAM, SI, MGAM2 HTT 4855/4885ALDH1A1 796/4885RAB9A 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback